Robust Immune Reconstitution in Children with Severe Primary Immunodeficiency after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation
William Tse(Lurie Children's Hospital), Morris Kletzel(Lurie Children's Hospital), Sonali Chaudhury(Northwestern University), Ramsay Fuleihan(Lurie Children's Hospital), Reggie Duerst(Lurie Children's Hospital), Jessica Ward(Northwestern University), Jennifer Schneiderman(Northwestern University)
Cited by 1
Related Papers
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
|Blood|2016|333
Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
|Transplantation and Cellular Therapy|2013|248
Unrelated Donor Cord Blood Transplantation for Children with Severe Sickle Cell Disease: Results of One Cohort from the Phase II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
|Transplantation and Cellular Therapy|2012|201
A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease
|Transplantation and Cellular Therapy|2020|201
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2021|183